Certainly! Chronic Myelomonocytic Leukemia (CMML) is a type of blood cancer that is relatively rare, with about 1,100 diagnoses each year in the United States. Here are some key points about CMML:
- **Prevalence and Demographics**: CMML is more common in older adults, with about 90% of cases diagnosed in individuals who Show Full Answer
Certainly! Chronic Myelomonocytic Leukemia (CMML) is a type of blood cancer that is relatively rare, with about 1,100 diagnoses each year in the United States. Here are some key points about CMML:
- **Prevalence and Demographics**: CMML is more common in older adults, with about 90% of cases diagnosed in individuals who are at least 60 years old. Men are twice as likely to develop CMML compared to women.
- **Disease Characteristics**: CMML develops from monocytes, which are a type of white blood cell important for immune system function. There are different subtypes of CMML, which can affect symptoms and outcomes.
- **Prognosis Factors**: Several factors influence the prognosis of CMML, including age, other health conditions, blood cell counts, genetic changes in CMML cells, and levels of lactate dehydrogenase (LDH) in the blood.
- **Survival Rates**: The survival rates vary by subtype:
- About 20% of people with type 0 or 1 CMML live for five years or more after being diagnosed.
- About 10% of people with type 2 CMML live for five years or more after diagnosis.
- **Progression to AML**: A significant percentage of CMML patients may develop Acute Myeloid Leukemia (AML) over time. The likelihood varies based on the subtype of CMML:
- About 15% to 30% of all CMML patients may develop AML.
- Specifically, about 18% of type 0 or 1 CMML patients and about 63% of type 2 CMML patients are diagnosed with AML within five years.
These details should provide a comprehensive overview of Chronic Myelomonocytic Leukemia. If you need more specific information or have other questions, feel free to ask!
May 9, 2024
Continue with Facebook
Sign up with your email
